Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab in Mild Allergic Asthma
NCT05740748Phase 2Unknown
- Sponsor
- McMaster University
- Start
- Apr 2023
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tezepelumab in allergic asthma, sponsored by McMaster University. Status: unknown.
02
Drugs
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT05740748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05740748.